On November 28, Zhixiang Jintai stated on the interaction platform that the company's Selinexor monoclonal injection (Jinlixi) was approved for listing in August 2024 and did not make it to the 2024 national medical insurance negotiation.
智翔金泰：赛立奇单抗注射液未赶上2024年国家医保谈判
Zhixiang Jintai: The Selinexor monoclonal injection did not make it to the 2024 national medical insurance negotiation.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th